Reverse Commute

Messina, Judith
June 2003
Crain's New York Business;6/23/2003, Vol. 19 Issue 25, p15
The news that Pfizer Inc. planned to shift 1,000 jobs to Manhattan, New York from New Jersey, Missouri, Michigan and California took many by surprise. Since Sept. 11, 2001 almost all the major relocation traffic has been headed in the opposite direction. However, the pharmaceutical giant, which acquired Warner-Lambert in 2000 and completed its purchase of Peapack, New Jersey-based Pharmacia, is convinced that it can save $2.5 billion over three years by consolidating many of its operations in the city. Pfizer believes workforce consolidation is the key to successfully running a business and it does need to consolidate. Under pressure to meet cost and earnings expectations promised by the mergers, Pfizer is closing some operations and shifting major functions to a few localities, such as Connecticut for research and development and New Jersey for its consumer business. To accommodate thousands of additional employees who will relocate to or be hired in Manhattan, Pfizer will invest $400 million to buy and renovate a 31-story building at 685 Third Avenue. INSET: Worth the trip.


Related Articles

  • Pfizer buys Pharmacia for $60bn. McKenna, Claire // BMJ: British Medical Journal (International Edition);7/20/2002, Vol. 325 Issue 7356, p123 

    Reports that Pfizer has purchased Pharmacia, a rival pharmaceutical company. Position of Pfizer as the world's leading pharmaceutical company; Competition between Pfizer and GlaxoSmithKline; Products which will be gained by Pfizer through the merger, including the arthritis drug Celebrex.

  • Incretin mimetics vie for slice of type 2 diabetes market. Shaffer, Catherine // Nature Biotechnology;Mar2007, Vol. 25 Issue 3, p263 

    The article reports that New York-based Pfizer's acquisition of BioRexis Pharmaceutical has made it one of the growing number of companies looking for a share of the worldwide market in diabetes. The increase of the interest of pharmaceutical companies in novel targets for injectable...

  • Pfizer acquires UK drug delivery technology firm.  // PharmaWatch: Biotechnology;November 2004, Vol. 3 Issue 11, p19 

    Reports that industry leading pharmaceuticals group Pfizer is set to pay $125 million to fully acquire Meridica Ltd., a drug delivery technology company based in Cambridge, England. Expected completion of the transaction in the fourth quarter of 2004; Background on Meridica.

  • OTC: REPORTERS Notebook.  // Drug Store News;1/15/2007, Vol. 29 Issue 1, p49 

    The article reports on the acquisition of Pfizer Inc. by Johnson & Johnson Inc. (Johnson & J) in December 2006 in the U.S. With the effort, Johnson & J Consumer Group portfolio will feature products including Listerine oral care products, Nicorette line of smoking cessation treatments and...

  • Pfizer to Buy CSL Animal Health.  // Chemical Market Reporter;12/22/2003, Vol. 264 Issue 22, p3 

    Reports on the acquisition of CSL Animal Health, a division of the Melbourne-based biopharmaceutical firm, CSL Ltd. by Pfizer Animal Health. Terms and details of the acquisition; Acquisition of access to CSL line of livestock and companion animal vaccines, a sales force and manufacturing...

  • A Slow Year Picked Up at the End. Drake, Diana Lasseter // njbiz;1/13/2003, Vol. 16 Issue 2, p18 

    Analyzes the decision of pharmaceutical company Pfizer to acquire Pharmacia. Relevance of the acquisition to the pharmaceutical industry in New Jersey; Overview of the deal; Trend in mergers and acquisitions in the industry. INSET: TOP 20 MERGERS AND ACQUISITIONS IN 2002.

  • Pfizer's Big Buy Changes Everything. Quinn, William T. // njbiz;7/22/2002, Vol. 15 Issue 30, p9 

    Discusses the merger between pharmaceutical companies Pfizer and Pharmacia in the U.S. Impact of the merger on the pharmaceutical industry; Background on the two companies; Details on the reorganization of Pfizer after its acquisition by Warner-Lambert in Morris Plains, New Jersey. INSETS:...

  • Pharmaceutical Industry Continues to Consolidate.  // Global Finance;Sep2002, Vol. 16 Issue 9, p22 

    Reports the acquisition of the pharmaceutical company Pharmacia by Pfizer in the U.S. Combination of research and development initiative; Production of the pharmaceutical products; Increase of revenue.

  • Pfizer Giving $195M for Encysive.  // Bioworld Week;2/25/2008, Vol. 16 Issue 8, p3 

    The article reports on the acquisition of Encysive Pharmaceuticals Inc. by Pfizer Inc. for an amount of almost $195 million in Houston, Texas. It notes that acquisition agreement gives Pfizer the rights to pulmonary arterial hypertension treatment called Thelin, as well as Encysive's other...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics